Prostate Cancer Compound Granted U.S. Patent

(USPTO.gov)

Adamis Pharmaceuticals Corp. in San Diego, California says the technology behind its cancer drug candidate has received a patent from the U.S. Patent and Trademark Office. Claims in patent 7863324 “Chroman-Derived Compounds for the Treatment of Cancer” include methods for inhibiting the growth of prostate cancer cells, delaying the progression of prostate cancer, and  preventing the recurrence of prostate cancer.

Pre-clinical studies of APC-100 for the treatment of prostate cancer were conducted by a team led by George Wilding at the University of Wisconsin Carbone Cancer Center. Those studies indicated APC-100 increased time to tumor progression and survival, and induced a significant decrease in Prostate Specific Antigen (PSA) production.

Adamis recently received approval from the FDA to begin Phase 1 and 2 clinical trials with APC-100 in men with castrate resistant prostate cancer. Each patient will be assessed for toxicity, biochemical responses, PSA, radiographic, and clinical responses. The study at University of Wisconsin and Wayne State University is scheduled to begin shorty.

Development of APC-100 has been funded by grants from National Cancer Institute, the Prostate Cancer Foundation, and Department of Defense Congressionally Directed Medical Research Program.

Read more: Patent Awarded for Protein Biomarker Cancer Screening

*     *     *